SEK 0.73
(2.11%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 6.59 Million SEK | 31.24% |
2022 | 5.02 Million SEK | 45.05% |
2021 | 3.46 Million SEK | 126.68% |
2020 | 1.52 Million SEK | 0.0% |
2019 | - SEK | 0.0% |
2018 | - SEK | 0.0% |
2017 | - SEK | 0.0% |
2016 | - SEK | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 1.18 Million SEK | -57.82% |
2024 Q2 | 1.27 Million SEK | 7.5% |
2023 Q4 | 2.81 Million SEK | 63.68% |
2023 Q3 | 1.71 Million SEK | 57.33% |
2023 FY | 6.59 Million SEK | 31.24% |
2023 Q2 | 1.09 Million SEK | 12.58% |
2023 Q1 | 970 Thousand SEK | 0.0% |
2022 Q1 | - SEK | 0.0% |
2022 FY | 5.02 Million SEK | 45.05% |
2022 Q3 | - SEK | 0.0% |
2022 Q2 | - SEK | 0.0% |
2022 Q4 | - SEK | 0.0% |
2021 Q3 | - SEK | 0.0% |
2021 FY | 3.46 Million SEK | 126.68% |
2021 Q4 | - SEK | 0.0% |
2020 FY | 1.52 Million SEK | 0.0% |
2019 FY | - SEK | 0.0% |
2018 FY | - SEK | 0.0% |
2017 FY | - SEK | 0.0% |
2016 FY | - SEK | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
AlzeCure Pharma AB (publ) | -476 Thousand SEK | 1484.874% |
BioGaia AB (publ) | 950.19 Million SEK | 99.306% |
Enzymatica AB (publ) | 31.86 Million SEK | 79.311% |
Enorama Pharma AB (publ) | -3.9 Million SEK | 268.982% |
Gabather AB (publ) | - SEK | -Infinity% |
Klaria Pharma Holding AB (publ.) | -9000.00 SEK | 73344.444% |
Moberg Pharma AB (publ) | -2.09 Million SEK | 414.054% |
Nanexa AB (publ) | 59.15 Million SEK | 88.857% |
Newbury Pharmaceuticals AB (publ) | 16.03 Million SEK | 58.885% |
ODI Pharma AB | -1.34 Million SEK | 591.341% |
Orexo AB (publ) | 549.9 Million SEK | 98.801% |
Probi AB (publ) | 220.21 Million SEK | 97.007% |
Swedencare AB (publ) | 164.8 Million SEK | 96.0% |
Swedish Orphan Biovitrum AB (publ) | 14.05 Billion SEK | 99.953% |
Toleranzia AB | -919 Thousand SEK | 817.301% |
Vivesto AB | -10.65 Million SEK | 161.862% |